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Introduction
The sixth workshop of the IDEAL leprosy consortium was held in Beijing from 23–25
August 2010, attended by 24 members of the consortium and invited guests from the Beijing
Tropical Medical Institute at the Beijing Friendship Hospital and from the Bellingham
Research Institute in Seattle. Partners attending this workshop came from China, Brazil,
Colombia, Ethiopia, India, Japan, Nepal, Netherlands, Pakistan, Philippines, South Korea,
Thailand, UK and USA.
The meeting opened with a special tribute to Dr. Huan Ying Li, of the Beijing Tropical
Medicine Research Institute, who recently celebrated her 90th birthday and who has been for
over 35 years a major force within the leprosy control and research programmes in China.
Notwithstanding the fact that there has been remarkable progress in reducing the number
of registered cases of leprosy worldwide and that drug resistance to the components of the
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multi-drug therapy used to treat leprosy remains very low, new incident cases of leprosy are
not declining in many countries. Even more worrying is the fact that many of these new cases
are positive for acid fast bacilli and so potentially infectious, thus we can expect transmission
to be continuing and new cases to develop over the next 5–20 year period. There is therefore
still a need for new diagnostic tools for improved tracking of this ongoing leprosy
transmission as well as to help diagnose individuals with new (subclinical) infections, in
order to minimise the development of nerve damage and subsequent deformities. The first day
was devoted to a general overview of the status of leprosy research within the partners’
institutions, and of the relevant leprosy control programmes.
MOLECULAR EPIDEMIOLOGY
The molecular epidemiology group of IDEAL has achieved the goals set for this period of
funding, namely to develop a set of molecular markers with which to compare strain diversity
and as tools to investigate outstanding questions that are a priority for field control and
clinical management of leprosy cases. Research within the group has established a panel of 14
reliable VNTR markers and has, in addition, identified markers that have proved less reliable
and should be excluded from further analyses. The first results of the molecular epidemiology
studies, led by Dr. Vara Vissa at CSU and Dr. Tom Gillis from NHDP and which included
sample collection and testing in Brazil, Mexico, Colombia, China, India, Thailand and the
Philippines, were recently published in a special issue of Leprosy Review.1 This set of
markers has provided a reliable, high-resolution basis for the identification of M. leprae
isolates. In order to complete the datasets some further work is needed on M. leprae isolates
from these countries.
Further insight into the global population structure of M. leprae and migration of the
bacteria between countries can be gained by combining the results of the SNP studies from
Dr. Stewart Cole’s group with the above studies and analysing them as a whole. Dr. Stephen
Salipante and Dr. Barry Hall from Bellingham Research Institute have proposed a new way in
which these data sets can be analysed, the NearestNeighbors programme. This programme
permits the user to quickly determine the nearest neighbour of a new isolate among isolates in
a database. Dr. Barry Hall has initiated a database in which the profiles of M. leprae strains
will be maintained, which will be curated by him initially. The database can be accessed and
downloaded through the Bellingham Research Institute website at http://web.me.com/
barryghall/Leprosy/Database/Database.html. In future it is anticipated that the database will
be curated at a university or large research institution, and will be expanded to include a
relational database with direct web access and with the possibility of immediate analysis
through a web interface.
It will be worth conducting an analysis of M. leprae strain types at sites where intervention
studies are likely to be undertaken, if such information is not yet available. The workshop
participants identified a number of important and clinically relevant studies where the new
VNTR panel could be used to answer important questions. These include whether there are
particular M. leprae strain types that are associated with the development of nerve damage or
reactions such as ENL, the frequency of which is known to be geographically variable. This
methodology can also be used to study possible animal or environmental reservoirs, and for
investigating the links between particular strains and trends in incidence in areas of changing
epidemiology. It was agreed that since the relapse rate is currently so low it is very difficult to
examine strains from relapse cases to determine whether relapse or re-infection is occurring.
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IMMUNODIAGNOSTICS – CELLULAR ASSAYS
The T cell group of IDEAL, which is led by Dr. Annemieke Geluk at LUMC, has been
developing tools that could be used to identify infection with M. leprae (see Figure 1).
Earlier studies (2005–2008) by the IDEAL consortium had found it difficult to replicate
in other endemic regions the initial promising specificity seen in M. leprae infected patients
and household contacts in Brazil. One challenging issue has been the presence of positive
responses in groups of healthy endemic controls. New studies (2009–2010) have now
identified a larger number of M. leprae antigens (proteins as well as peptides) that can induce
M. leprae specific T cell responses in the absence of any recognition by patients with
tuberculosis. These promising antigens will now be tested further in other sites with various
levels of endemicity. Additional studies have supported the hypothesis that such T cell
responses to M. leprae unique antigens in endemic controls are associated with the level of
M. leprae endemicity within that community, and may indicate that in areas where significant
leprosy transmission is still continuing, many individuals within the community are being
exposed to, and subclinically infected with, M. leprae. Another area of investigation of the T
cell group is whether the biosignature within antigen-stimulated blood cultures can be used to
distinguish individuals who are developing clinical disease from those who have been
exposed and infected but who are likely to remain healthy. Very promising results are being
obtained at LUMC in new multiplex assays that indicate that such an approach may well
enable these groups to be distinguished based on their immunological profile.
1st T cell study:
Ag set #1
LST and WBA
Genetic variability
5 sites
"Go/ no-Go" Ags
Improve peptide 24 h WBA:
New Ag CSU, IDRI, LUMC
Additional CMI
biomarkers
Serological markers
Field-friendly LF test
development
2nd T cell study:
Ag set #2
WBA
Feedback field
site feasibility
Field study aim:
Test larger cohort
Identify HHC that are infected
Predict clinical leprosy in HHC
Diagnostic
test
Add cytokines and mAb
Identify specific peptides
Biom
arker profiles
Figure 1. Workplan immunodiagnostics group IDEAL 2005–2010.
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An additional aim of the T cell group of IDEAL has been the development of simpler test
formats that would aid the use of a CMI-based test in the field. This new test format
development is based on a simple overnight whole blood assay, similar to the
QuantiFERONw-TB Gold In Tube test as used for TB, which could be followed by a
straightforward ELISA assay specific for IFNg. In addition, a field-friendly lateral flow assay
based on upconverting phosphor technology is being developed at the LUMC to determine
IFNg responses after whole blood stimulation.2 Of note is that this simple lateral flow assay
for IFNg analysis can also be performed in combination with other cytokines, as well as
specific antibodies to PGL-I. At IDRI a serology-based lateral flow assay for antibodies
directed against a combination of PGL-I and M. leprae recombinant proteins is currently
under development as well.
The tools described above would greatly facilitate diagnosis of leprosy in large scale
studies in the field, or in clinical settings.
WHAT’S NEXT? BRIDGE PROJECT TO PREPARE FOR A PHASE I I / I I I TRIAL
The exact design for an intervention study remains to be decided, but possibilities include a
chemoprophylaxis intervention within leprosy contacts, perhaps compared to vaccination
with a new M. leprae vaccine or with BCG. A site with sufficient numbers of new leprosy
cases, an adequate infrastructure and the experience to conduct such a trial will be needed.
A bridge project has been approved recently by MALTALEP with the title: ‘The
combined effect of chemoprophylaxis with rifampicin and immunoprophylaxis with BCG, in
the prevention of leprosy in contacts: a randomized controlled trial’. Single-dose rifampicin
has been shown to prevent 56% of incident cases of leprosy in the first 2 years, when given to
contacts of newly diagnosed cases. Immunisation of contacts with BCG has been less well
documented, but appears to have a preventive effect lasting up to 9 years; one major
disadvantage is the precipitation of excess cases within the first year after immunization. We
hypothesise that these two forms of prophylaxis could be complimentary, producing a more
pronounced preventive effect when given together. This hypothesis will be tested in a cluster
randomised controlled trial in Bangladesh, to compare BCG alone with BCG plus rifampicin,
in contacts of new leprosy cases; the intervention group will be given BCG followed by
rifampicin, two months later. In total 10,000 contacts will be included in each intervention
arm. Follow-up will take place over the following year. The outcome is the occurrence of
clinical leprosy within this year.
This project will provide a platform for larger future trials in which interventions can be
further field-tested and in which the diagnostic and molecular epidemiology tools that have
been developed within IDEAL can be applied and further refined for field application. These
larger future trials will also provide a platform for the simpler test formats developed in the
T cell group of IDEAL for analysis of M. leprae infection and subsequent prediction of
disease development.
Conclusion
Leprosy is no longer considered to be a major public health problem. Certainly there has been
remarkable progress in reducing the number of prevalent cases, and the lack of significant
drug-resistance to the MDT regimen should mean that the new cases being diagnosed can be
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successfully treated. However, the challenge of similar yearly numbers of emerging new
cases and the problem of reactions and nerve damage, leading to disability, remain serious
issues and it is hoped that the new tools that are being developed within the IDEAL
Consortium will contribute to the identification of new cases at an early stage, and to reduce
further transmission and the development of disability.
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